Capitalization 11.74B P/E ratio 2025 *
61.6x
P/E ratio 2026 * 47.9x
Enterprise value 11.63B EV / Sales 2025 *
9.58x
EV / Sales 2026 * 8.53x
Free-Float
98.97%
Yield 2025 *
0.43%
Yield 2026 * 0.45%
More valuation ratios * Estimated data
Dynamic Chart
1 day-4.43%
1 week-5.20%
Current month-7.42%
1 month+3.16%
3 months+3.57%
6 months+9.03%
Current year-4.10%
More quotes
1 week
73.89
Extreme 73.89
80.02
1 month
70.81
Extreme 70.81
80.95
Current year
61.16
Extreme 61.16
85.57
1 year
51.79
Extreme 51.79
85.57
3 years
51.79
Extreme 51.79
132.95
5 years
38.79
Extreme 38.7925
135.96
10 years
19.99
Extreme 19.9875
135.96
More quotes
Director TitleAgeSince
Chief Executive Officer 57 18-04-29
Director of Finance/CFO 53 14-03-31
Investor Relations Contact - 19-09-30
Manager TitleAgeSince
Chairman 68 02-12-31
Director/Board Member 74 89-12-31
Director/Board Member 54 09-05-18
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-4.43%-5.20%+11.28%-40.06%11.74B
+0.19%-1.48%+28.20%-23.42%45.05B
-1.88%-3.74%+19.23%-5.86%41.46B
-0.74%-1.84%+55.88%+39.88%34.6B
-2.25%-5.45%+37.21%-18.30%29.51B
-0.41%+2.46%+21.94%+11.76%24.28B
-3.31%-4.47%-40.75%-82.10%23.48B
-0.68%-2.14%+58.05%+88.31%15.58B
+0.26%+3.52%+40.78%+72.65%10.45B
-1.72%-4.37%-1.09%-54.50%9.79B
Average -1.06%-1.32%+23.07%-1.16% 24.59B
Weighted average by Cap. -0.91%-1.89%+24.91%-3.94%
See all sector performances
2025 *2026 *
Net sales 1.21B 1.34B
Net income 203M 261M
Net Debt -110M -348M
More financial data * Estimated data
Logo Bio-Techne Corporation
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Employees
3,100
More about the company
Date Price Change Volume
24-10-04 74.98 $ +1.32% 47,987
24-10-03 74.00 $ -4.43% 1,142,897
24-10-02 77.43 $ -0.95% 714,087
24-10-01 78.17 $ -2.20% 744,199
24-09-30 79.93 $ +1.54% 721,138

Delayed Quote Nasdaq, October 03, 2024 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
74.00USD
Average target price
83.09USD
Spread / Average Target
+12.29%
Consensus